Detail akcie CardioGenics online

Business Summary: CardioGenics Holdings Inc. is engaged in business of development of products targeting the immunoassay segment of the point-of-care in vitro diagnostic (IVD) testing market. The Company is engaged in development of technology and products, which include The QL Care Analyzer (QLCA), Cardiovascular Tests and Paramagnetic beads. The QLCA is a point-of-care (POC) immunoassay analyzer. The QLCA uses a self-metering cartridge to perform immunoassay tests at the POC. To support the use of the QLCA, the Company develops approximately four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack. Its immunoassay tests include Troponin I (TnI), Plasminogen Activator Inhibitor Type-1 (PAI-1), Heart Failure Risk Stratification (HFRS) and Heart Failure Genomics Risk (HFGR). The Company's TnI test product is in the pilot testing phase. Paramagnetic (magnetic) beads are the solid phase employed during immunoassays tests.
Financial Summary: BRIEF: For the three months ended 31 January 2016, CardioGenics Holdings Inc revenues was not reported. Net loss decreased 88% to $125K. Lower net loss reflects G/L on Invest. HFS, Maturity & Trading increase from $652K (expense) to $55K (income), Loss (Gain) on Foreign Exchange Transact increase from $44K (expense) to $147K (income), Interest Expense and Bank Charges (Net) decrease of 21% to $126K (expense).